Načítá se...
Development and characterization of novel anti‐C5 monoclonal antibodies capable of inhibiting complement in multiple species
Over the last decade there has been an explosion in complement therapies; one‐third of the drugs in the clinic or in development target C5 protein. Eculizumab, a monoclonal antibody (mAb) that binds C5 and blocks its cleavage by the convertase, is the current reference standard treatment for atypica...
Uloženo v:
| Vydáno v: | Immunology |
|---|---|
| Hlavní autoři: | , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
John Wiley and Sons Inc.
2019
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6620185/ https://ncbi.nlm.nih.gov/pubmed/31120547 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/imm.13083 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|